Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS: Drug Evaluators Seek Comments

Image Source: IMGARCADE

Got an opinion on which MSs drugs work best?

The Institute for Clinical and Economic Review (ICER) is looking for comment on its report on the comparative clinical effectiveness and value of disease modifying therapies for relapsing remitting and primary progressive MS.

ICER, a non-profit research institute that reviews the efficacy of drugs, is also welcoming draft voting questions until December 21 at 5 p.m. Eastern time.

In statement, ICER explained that they are “committed to engaging with all stakeholders in a thorough and transparent manner,” and said that before releasing the Draft Evidence Report, ICER spoke with key stakeholders such as patient groups, clinical experts, and drug manufacturers to include and engage them in the process. 

Of 16 disease modifying therapies under review, only one does currently not have U.S. Food and Drug Administration approval, though it is expected to be granted by the end of the year (ocrelizumab), and one other drug is approved for other conditions and is used off label for MS (rituximab). The subcutaneous injection drugs included in the ICER review are: interferon B-1a (Avenoex/Biogen), interferon B-1b (Betaseron/Bayer), interferon B-1b (Extavia/Novartis), glatirameracetate 20 mg (Copaxone/Teva), glatirameracetate 40 mg (Copaxone/Teva), glatirameracetate 20 mg (Glatopa/Sandoz), interferon B-1a (Rebif/ EMD Serono), peginterferon B-1a (Plegridy/ Biogen) and daclizumab (Zinbryta/ Biogen and AbbVie). The review also includes three oral drugs (fingolimod [Gilenya, Novartis], teriflunomide [Aubagio, Sanofi Genzyme], and dimethyl fumarate [Tacfidera, Biogen]) in addition to four intravenous infusions: natalizumab (Tysabri/ Biogen), alemtuzumab (Lemtrada/ Sanofi Genzyme), ocrelizumab (Ocrevus,/Genentech), and rituximab (Rituxan/ Genentech). 

In the report, ICER explained that through discussions with advocacy organizations, they learned that while some patients have strong preferences for oral medications over injectables – this could be potentially due to their dislike of needles, injection site reactions, and the difficulty of storing medications that require refrigeration.

However, ICER added, some patients are equally comfortable with medications. The advocacy groups also highlighted that patients sometimes have a low tolerance for risk and tend not to choose DMTs with known, potentially severe side effects. 

The Evidence Report will be presented at a public meeting of the California Technology Assessment Forum (CTAF) on February 16, 2017 in Oakland, CA

The CTAF will vote on questions raised in the report at the meeting and a panel of experts will host a roundtable discussion surrounding recommendations to apply the evidence to new policy and practice guidelines. At this meeting, there will be an allotment of time for stakeholders to make oral comments on the report – requests for oral comment are also being accepted until December 21 at 5 p.m.

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length
Click here to read more

Go to Newer News Go to Older News